---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004151"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:33:26.897433+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Jazz Pharma reaffirms FY2022 revenue guidance at J.P. Morgan conference

## Summary
- Company expects to meet previously announced total, neuroscience and oncology revenue guidance for FY2022.
- Presentation includes corporate overview and financial update; no change to existing guidance ranges.
- No specific revenue or earnings figures disclosed in the filing.

## SEC filing metadata
- accession: 0001193125-23-004151
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312523004151/0001193125-23-004151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312523004151/d442750d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004151
- JSON: https://secwatch.observer/filing/0001193125-23-004151.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004151.txt

## Key facts
- Earnings Releases
  Jazz Pharmaceuticals plc updated its year ended December 31, 2022 guidance (reaffirmed).
  - Period: year ended December 31, 2022
  - Guidance: reaffirmed
  - Result: guidance update
  source text: the Company’s expectations that it will meet its previously announced total, neuroscience and oncology revenue guidance ranges for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000119312523004151/0001193125-23-004151-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.